AlgiPharma
  • Home
  • The Team
  • Technology
  • About Us
  • Clinical Trials
  • News
  • Search
  • Menu Menu

News

AlgiPharma Attends the LNP Summit Congress in London

October 1, 2022/in News

AlgiPharma attends and presents data on its alginate oligosaccharide technology platform at the Lipid Nanoparticles Development Summit 18th-20th October in London.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-10-01 12:32:472023-03-14 12:33:38AlgiPharma Attends the LNP Summit Congress in London

AlgiPharma Adds to its Intellectual Property Portfolio

August 1, 2022/in News

AlgiPharma was recently granted patent protection for its United States Patent No. 11413306 (15/766272) National Phase of PCT Application PCT/EP2016/073931 for “Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract”. This adds to AlgiPharma’s growing patent portfolio.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-08-01 12:25:102023-03-14 12:26:05AlgiPharma Adds to its Intellectual Property Portfolio

AlgiPharma Attends Annual European Cystic Fibrosis Congress in Rotterdam

June 1, 2022/in News

AlgiPharma attends the annual ECFS congress in Rotterdam, continuing to support and learn about new developments for the treatment of people with Cystic Fibrosis.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-06-01 12:33:482023-03-14 12:36:40AlgiPharma Attends Annual European Cystic Fibrosis Congress in Rotterdam

AlgiPharma Adds to its Intellectual Property Portfolio

May 1, 2022/in News

AlgiPharma was recently granted patent protection in its ongoing National Phase of PCT Application PCT/EP2017/076926 for “Bacitracin-alginate oligomer conjugates”. This adds to AlgiPharma’s growing patent portfolio.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-05-01 12:21:392023-03-14 12:23:35AlgiPharma Adds to its Intellectual Property Portfolio

AlgiPharma Adds to its Intellectual Property Portfolio

April 1, 2022/in News

AlgiPharma was recently granted patent protection for its European Patent No. 3528830 (17791037.9) Polymyxin-alginate oligomer conjugates. This adds to AlgiPharma’s growing patent portfolio.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-04-01 12:20:022023-03-14 12:21:28AlgiPharma Adds to its Intellectual Property Portfolio

AlgiPharma Study Published on Potentiation of Colistin.

March 1, 2022/in News

AlgiPharma’s collaboration partners in Cardiff University have recently published an article on the potentiating effects of AlgiPharma’s alginate oligosaccharide technology:   Stokniene J, Varache M, Rye PD, Hill KE, Thomas DW, Ferguson EL. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Sci Rep. 2022 Mar 23;12(1):4986. doi: 10.1038/s41598-022-08927-1. PMID: 35322119; PMCID: […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-03-01 12:16:452023-03-14 12:19:14AlgiPharma Study Published on Potentiation of Colistin.

AlgiPharma Phase 2 Burkholderia Study Published.

February 1, 2022/in News

AlgiPharma in collaboration with its clinical trials team for the randomized clinical trial NCT02453789 in CF has recently been published: Fischer R, Schwarz C, Weiser R, Mahenthiralingam E, Smerud K, Meland N, Flaten H, Rye PD. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros. […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-02-01 12:13:362023-03-14 12:16:10AlgiPharma Phase 2 Burkholderia Study Published.

AlgiPharma in the News: GlobalNewswire and DelveInsight’s Business Report.

January 27, 2022/in News

January 27th 2022 AlgiPharma was featured in DelveInsights’s “Cystic Fibrosis Pipeline Insight, 2022” report that provides insight on company and pipeline activities in the Cystic Fibrosis therapeutics landscape. The report highlights around 60+ products under development by companies working on novel opportunities that could influence Cystic Fibrosis treatment. The report provides insights into different therapeutic […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2022-01-27 11:56:552022-02-04 12:01:53AlgiPharma in the News: GlobalNewswire and DelveInsight’s Business Report.

AlgiPharma secures 22 MNOK in non-dilutive funding for development of its antimicrobial alginate oligosaccharide technology, with the goal to enhance fighting multidrug resistance.

December 20, 2021/in Awards, News

AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Councils Innovation Project for the Industrial Sector program for the project “Therapeutic Alginates for Resistant and Recurrent Infections: Generating Eradication Therapies (TARRGET)”. The project grant awarded from the Research Council combined with the Norwegian government tax incentive scheme (SkatteFUNN) results in a […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2021-12-20 09:27:472021-12-20 09:27:47AlgiPharma secures 22 MNOK in non-dilutive funding for development of its antimicrobial alginate oligosaccharide technology, with the goal to enhance fighting multidrug resistance.

AlgiPharma awarded 16 MNOK grant from the Norwegian Research Council’s Innovation Project for the Industrial Sector program.

October 6, 2020/in Awards, News

AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Council.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2020-10-06 09:47:072020-10-06 09:48:43AlgiPharma awarded 16 MNOK grant from the Norwegian Research Council’s Innovation Project for the Industrial Sector program.

AlgiPharma is Recruiting – Again!

May 14, 2020/in News

Director Clinical Research / Chief Medical Officer AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. The deadline for applications is the 24th May 2020 (see links below for further details). More details can be found at: – www.borka.no/jobb/director-clinical-research-chief-medical-officer/ – www.finn.no/177948590 – www.linkedin.com/groups/2085624 – […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2020-05-14 14:21:332020-05-14 14:23:55AlgiPharma is Recruiting – Again!

New parent company in the AlgiPharma group

January 22, 2020/in News

AlgiPharma AS acquired by AlgiPharma AB On December 20, 2019 the Swedish AlgiPharma AB finalized the acquisition of the Norwegian AlgiPharma AS. All shareholders in AlgiPharma AS accepted the offer from AlgiPharma AB which means that the shareholders have the same number of shares and ownership percentage in the new parent company AlgiPharma AB as […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2020-01-22 13:37:222020-01-22 13:37:22New parent company in the AlgiPharma group

AlgiPharma appoints new CFO

August 1, 2019/in News

AlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO) Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2019-08-01 18:13:482019-08-12 18:16:18AlgiPharma appoints new CFO

AlgiPharma is Recruiting

April 30, 2019/in News

AlgiPharma announces two new positions avaliable. AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway. The deadline for applications is the 12th May 2019 […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2019-04-30 10:55:412019-05-08 10:53:09AlgiPharma is Recruiting

New 2b Clinical Trial started in Australia

April 30, 2019/in News, Phase 2

New Phase 2b Clinical Trial: A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205) A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2019-04-30 10:18:382019-06-04 13:51:06New 2b Clinical Trial started in Australia

AlgiPharma Appoints Director for Australian Operations

January 1, 2019/in News

AlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand. About Cystic Fibrosis: Cystic […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2019-01-01 10:43:382019-05-08 10:45:19AlgiPharma Appoints Director for Australian Operations

Innovation Award Winner for 2018

December 7, 2018/in Awards, News
Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2018-12-07 22:14:332018-12-07 22:14:33Innovation Award Winner for 2018

AlgiPharma registers new company in Australia

November 21, 2018/in News

AlgiPharma has registered a new proprietary limited company in Melbourne, Australia.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2018-11-21 10:11:192018-11-21 10:11:19AlgiPharma registers new company in Australia

AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme

January 15, 2018/in Awards, News

An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2018-01-15 16:09:232018-01-30 11:48:23AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme

AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)

January 15, 2018/in Awards, News

AlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2018-01-15 15:42:412018-01-30 09:46:32AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)

AlgiPharma awarded 4 year grant from the Norwegian Research Council’s NANO2021 programme

January 15, 2018/in Awards, News

AlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2018-01-15 15:19:032018-01-15 15:43:43AlgiPharma awarded 4 year grant from the Norwegian Research Council’s NANO2021 programme

Hilde Morris joins AlgiPharma

November 9, 2017/in News

Hilde Morris has recently been appointed to replace our outgoing clinical director.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2017-11-09 08:03:192017-11-11 08:05:30Hilde Morris joins AlgiPharma

AlgiPharma collaboration with Cardiff University wins Medical Innovation Award

June 28, 2017/in Awards, News

AlgiPharma collaboration wins Cardiff University’s prestigious Medical Innovation Award

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2017-06-28 00:10:352017-07-04 11:12:10AlgiPharma collaboration with Cardiff University wins Medical Innovation Award

AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG

June 3, 2016/in Awards, News

AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2016-06-03 15:00:592016-06-16 00:26:10AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG

AlgiPharma features in CFF drug development pipeline

May 4, 2016/in News

AlgiPharma now features on the Cystic Fibrosis Foundation (CFF) drug development pipeline

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2016-05-04 12:03:102016-06-03 11:07:28AlgiPharma features in CFF drug development pipeline

AlgiPharma signs new license agreement with NTNU

March 9, 2016/in News

AlgiPharma secures new license agreement with NTNU for exclusive global rights.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2016-03-09 12:43:002016-05-25 09:01:10AlgiPharma signs new license agreement with NTNU

AlgiPharma granted Orphan Drug designation by FDA

February 24, 2016/in News

AlgiPharma granted Orphan Drug designation by FDA

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 Philip Rye https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png Philip Rye2016-02-24 12:31:392016-05-25 09:01:39AlgiPharma granted Orphan Drug designation by FDA

AlgiPharma starts two new Phase 2b trials in Cystic Fibrosis

February 20, 2015/in News, Phase 2

AlgiPharma has started preparations for two new clinical phase 2b trials in cystic fibrosis patients.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2015-02-20 15:05:142018-01-15 16:31:31AlgiPharma starts two new Phase 2b trials in Cystic Fibrosis

AlgiPharma awarded four year grant from Norwegian Research Council

February 12, 2015/in Awards, News

AlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2015-02-12 15:03:482016-06-03 10:56:47AlgiPharma awarded four year grant from Norwegian Research Council

Technology Strategy Board (Innovate UK) & Innovation Norway – New Funding Success

November 21, 2014/in Awards, News

Building on the previous success with the AlgiFerm project, AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), FMC Biopolymer, and SINTEF have secured additional funding from the UK’s Technology Strategy Board (now Innovate UK) and Innovation Norway for further investigation on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. The study will focus on developing methods for scaling-up microbial fermentation production of OligoG at CPI.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2014-11-21 15:02:542016-06-03 10:58:24Technology Strategy Board (Innovate UK) & Innovation Norway – New Funding Success

Technology Strategy Board & Innovation Norway – Algiferm Project Success

January 2, 2014/in News

The collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has been successful in achieving the project milestones.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2014-01-02 15:01:532016-05-25 09:03:50Technology Strategy Board & Innovation Norway – Algiferm Project Success

AlgiPharma awarded four year grant from Norwegian Research Council

July 19, 2013/in Awards, News

AlgiPharma has been awarded a four year grant from the Norwegian Research Council for the project “Tailored OligoG in the treatment of chronic infectious biofilms”.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2013-07-19 15:01:132016-06-03 10:59:12AlgiPharma awarded four year grant from Norwegian Research Council

Technology Strategy Board & Innovation Norway – New Funding Success 

April 19, 2013/in Awards, News

A collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has secured funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for a feasibility study on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2013-04-19 14:59:242016-05-25 09:06:36Technology Strategy Board & Innovation Norway – New Funding Success 

The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms

April 16, 2013/in Abstract, News

Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, Onsøyen E, Myrvold R, Hill KE, Thomas DW. Biofouling. 2013 Apr;29(4):413-21. doi: 10.1080/08927014.2013.777954. External link to Pubmed.gov Abstract The influence of a novel, safe antibiofilm therapy on the mechanical properties of Pseudomonas aeruginosa and Acinetobacter baumannii biofilms in vitro was characterized. A multiscale approach employing […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2013-04-16 14:57:422016-05-25 09:07:29The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms

AlgiPharma awarded secured 2.700.000 NOK for joint UK/Norwegian innovation project

February 5, 2013/in Awards, News

In collaboration with leading experts in fermentation at the Centre for Process Innovation (CPI, Newcastle, UK), Algipharma has secured combined funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for pilot scale studies for production of its promising new alginate oligomer drug candidate.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2013-02-05 15:00:192016-05-25 09:08:21AlgiPharma awarded secured 2.700.000 NOK for joint UK/Norwegian innovation project

NANO2021 NFR Program: Norwegian Research Council Funds AlgiPharma Consortium 9.750.000 NOK for advanced wound healing applications

October 13, 2012/in Awards, News

AlgiPharma is part of a multi-disciplinary consortium that has been awarded funding from the Research Council of Norway (NANO2021 programme).

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2012-10-13 14:56:222016-05-25 09:08:59NANO2021 NFR Program: Norwegian Research Council Funds AlgiPharma Consortium 9.750.000 NOK for advanced wound healing applications

BIOTEK 2021 Funding Success 4.000.000 NOK

October 3, 2012/in Awards, News

AlgiPharma together with FMC Biopolymer and SINTEF are part of the award winning research consortium co-ordinated by Dr. Gudmund Skjaak-Braek at the Norwegian National Biotechnology Institute (NTNU).

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2012-10-03 14:55:362016-05-25 09:09:39BIOTEK 2021 Funding Success 4.000.000 NOK

Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics

August 26, 2012/in Abstract, News

Khan S, Tøndervik A, Sletta H, Klinkenberg G, Emanuel C, Onsøyen E, Myrvold R, Howe RA, Walsh TR, Hill KE, Thomas DW. Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41. doi: 10.1128/AAC.00525-12. Epub 2012 Jul 23. External link to Pubmed.gov Abstract The uncontrolled, often inappropriate use of antibiotics has resulted in the increasing prevalence of antibiotic-resistant pathogens, with […]

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2012-08-26 14:53:072016-05-25 09:10:47Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics

Philip D. Rye and Astrid Hilde Myrset joins AlgiPharma

August 23, 2012/in News

Philip Rye (1962) came to AlgiPharma in 2012. Astrid Hilde Myrset (1956) is a biochemist by training, and joined AlgiPharma in 2012.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2012-08-23 14:51:052016-04-04 14:05:05Philip D. Rye and Astrid Hilde Myrset joins AlgiPharma

AlgiPharma wins €4,6 million EUROSTARS grant

July 25, 2011/in Awards, News

AlgiPharma has together with partners Smerud Medical Research and Simbec Research been awarded a EUROSTARS grant for a €4,6 million project.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2011-07-25 14:49:532016-04-04 13:52:32AlgiPharma wins €4,6 million EUROSTARS grant

AlgiPharma wins research grant from CFF

April 9, 2011/in Awards, News

AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2011-04-09 14:48:312016-05-25 09:12:30AlgiPharma wins research grant from CFF

AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis

April 1, 2011/in News, Phase 2

AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (Oligo-G) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2011-04-01 12:45:432016-05-25 09:13:12AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis

US Department of Defense supports an AlgiPharma initiated in vivo wound healing study on OligoG

August 30, 2010/in News

AlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2010-08-30 14:45:372016-06-03 11:03:52US Department of Defense supports an AlgiPharma initiated in vivo wound healing study on OligoG

AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

January 5, 2010/in News, Phase 1

Oligo-G CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2010-01-05 10:42:232016-05-25 09:14:20AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis

September 6, 2009/in News, Phase 1

A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2009-09-06 09:05:142016-04-04 13:43:20AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis

AlgiPharma wins NFR funding for basic research projects on biofilms

June 3, 2008/in Awards, News

The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2008-06-03 16:38:272016-06-03 11:05:47AlgiPharma wins NFR funding for basic research projects on biofilms

AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment

September 11, 2007/in News

AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2007-09-11 14:37:032016-03-16 14:38:17AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment

AlgiPharma Established

August 18, 2006/in News

On the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.

Read more
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png 0 0 rogerhenriksen https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png rogerhenriksen2006-08-18 18:30:542016-03-16 14:34:53AlgiPharma Established


Disclaimer / Privacy / Cookie Policy

Contact

AlgiPharma AS
Industriveien 33
N-1337 Sandvika
Norway

Phone: +47 67545770
Mail: post@algipharma.com

Recent news

  • AlgiPharma Attends the LNP Summit Congress in LondonOctober 1, 2022 - 12:32 pm
  • AlgiPharma Adds to its Intellectual Property PortfolioAugust 1, 2022 - 12:25 pm
© AlgiPharma / Web & design by Havdur Design
  • Home
  • The Team
  • Technology
  • About Us
  • Clinical Trials
  • News
Scroll to top